시장보고서
상품코드
1134155

세계의 신경성 통증 시장 예측(-2027년)

Global Neuropathic Pain Market Research Report Forecast to 2027

발행일: | 리서치사: Market Research Future | 페이지 정보: 영문 208 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 신경성 통증 시장 규모는 2027년까지의 조사 기간 중 6.3%의 현저한 CAGR로 성장하며, 2027년에는 287억 7,820만 달러를 돌파할 것으로 예측됩니다. 통증 관리 센터의 증가, 제네릭 의약품의 수요 증가, 당뇨병의 증가는 신경성 통증 시장의 성장을 촉진하고 있습니다.

세계의 신경성 통증 시장에 대해 조사분석했으며, 시장 역학, 시장 분석, 경쟁 구도, 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 서론

  • 정의
  • 조사 범위
  • 조사 목적
  • 시장 구조
  • 전제와 제한

제3장 조사 방법

  • 데이터 마이닝
  • 2차 조사
  • 1차 조사
  • 1차 응답자 내역
  • 예측 방법
  • 조사 방법 규모 추정을 위한 조사 방법
    • 보텀업 어프로치
    • 톱다운 어프로치
  • 데이터 삼각측량
  • 검증

제4장 시장 역학

  • 개요
  • 촉진요인
    • 당뇨병성 신경병증의 유병률 상승
    • 의료의 증가
    • 부상 및 기타 상태별 외상의 증가
  • 억제요인
    • 위조 의약품의 증가와 치료의 부작용
    • 신경학적 상태에 관한 인식의 결여
  • 기회
    • 개발도상 지역에서의 신제품 발매

제5장 시장 요인 분석

  • 밸류체인 분석
    • 연구개발
    • 제조
    • 유통과 판매
    • 판매 후 모니터링
  • Porter's Five Forces 모델
    • 공급 기업의 교섭력
    • 구매자의 교섭력
    • 신규 진출업체의 위협
    • 대체품의 위협
    • 경쟁의 강도
  • COVID-19의 영향 분석
    • 개요
    • 진행중인 치료에 대한 영향과 연기에 의한 이용 가능성의 지연
    • 환자 수에 대한 영향

제6장 세계의 신경성 통증 시장 : 유형별

  • 개요
  • 말초신경병증
  • 교액성 신경장애
  • 삼차 신경통
  • 환상지통
  • 대상포진 후 신경통(PHN)
  • 외상 후 신경장애

제7장 세계의 신경성 통증 시장 : 적응증별

  • 개요
  • 당뇨병성 신경병증
  • 척주관협착증
  • 화학요법에 따른 말초신경병증
  • 기타

제8장 세계의 신경성 통증 시장 : 진단별

  • 개요
  • 이미징
  • 혈액검사
  • 신체검사

제9장 세계의 신경성 통증 시장 : 치료별

  • 개요
  • 투약
  • 중다양식 치료(MULTIMODAL THERAPY)

제10장 세계의 신경성 통증 시장 : 유통경로별

  • 개요
  • 소매 약국과 드러그스토어
  • 온라인 약국

제11장 세계의 신경성 통증 시장 : 최종사용자별

  • 개요
  • 병원
  • 클리닉
  • 연구기관

제12장 세계의 신경성 통증 시장 : 지역별

  • 개요
  • 아메리카
    • 북미
    • 라틴아메리카
  • 유럽
    • 서유럽
    • 동유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동
    • 아프리카

제13장 경쟁 구도

  • 개요
  • 경쟁 벤치마킹
  • 세계의 신경성 통증 시장 : 기업 순위(2020년)
  • 세계 신경성 통증 시장의 주요 성장 전략
  • 개발 수에 의한 주요 기업
  • 경쟁 벤치마킹 : 세계의 신경성 통증 시장
  • 주요 개발과 성장 전략
    • 제품 승인과 발매
    • 인수
  • 재무 매트릭스

제14장 기업 개요

  • ABBOTT
  • PFIZER
  • JOHNSON & JOHNSON SERVICES, INC.
  • BAXTER INTERNATIONAL
  • ELI LILY AND COMPANY
  • GLAXOSMITHKLINE PLC
  • SANOFI
  • ASTRAZENECA
  • DEPOMED INC.(ASSERTIO THERAPEUTICS, INC)
  • BIOGEN, INC.
  • ASTELLAS PHARMA LTD.

제15장 부록

  • 참고 문헌
  • 관련 리포트
KSA 22.10.20

Global Neuropathic Pain Market Research Report - Forecast to 2027

Market analysis

Neuropathic Pain Market is anticipated to surpass USD 28,778.20 million by 2027 at a notable CAGR of 6.3% during the review period.

Neuropathic pain is prominently caused by the peripheral nerve disorder. The global market growth is attributed to the introduction of pain management centers along with higher demand for generic drugs.

In Neuropathic Pain Market, diabetes is one of the main sources of expanded neuropathic torment. The subsequent primary driver of neuropathic torment is the destructive infection called disease. According to World Health Organization (WHO) reports, in 2014, there were around 422 million individuals who were experiencing diabetes.

The huge populace is likewise viewed as one of the essential basic drivers of the market. Likewise, better treatment offices, improvement of medical care frameworks, ascend popularity of neuropathic torment and critical ventures by pharma organizations, improvement in nature of medications, and quantities of torment the board frameworks will push the market on a positive course.

Market segmentation

Based on type segment, the global neuropathic pain market has been classified into peripheral neuropathy, post-traumatic neuropathy, post-herpetic neuralgia (PHN), phantom limb pain, entrapment neuropathy, and trigeminal neuralgia. Based on indication, the market is divided into chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and spinal stenosis. In terms of diagnosis, the market is segmented into blood tests, imaging, and physical examination. Based on its treatment, the market is classified into medication type and multimodal therapy. The end-use industries include clinics, hospitals, and research organizations. Based on its distribution channels, the market is divided into online pharmacies and retail pharmacies & drug stores.

Regional analysis

The nations in North America and South America contained an all-out market esteem worth of USD 6,645.09 million in the year 2019. It is anticipated that it will arrive at a CAGR of around 5.6% during the gauge time frame. The rising number of problems connected with neuropathic torment, mechanical turns of events, and ascend in mindfulness are the fundamental elements of the Neuropathic Pain Market development.

The American market is grouped into North America and Latin America. The market of North America is additionally partitioned into the United States of America and Canada.

The neuropathic torment market in Western Europe has been isolated into France, the UK, Germany, Spain, Italy, and other European nations. The market in Asia-Pacific is sectioned into India, Japan, Australia, China, South Korea, and different nations in the Asia-Pacific area. The Market in the Middle East and African district is separated into the Middle East and Africa.

Major players

Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), among others, are some of the major players in the global neuropathic pain market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION 22
  • 2.2 SCOPE OF THE STUDY 22
  • 2.3 RESEARCH OBJECTIVE 22
  • 2.4 MARKET STRUCTURE 23
  • 2.5 ASSUMPTIONS & LIMITATIONS 24

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING 25
  • 3.2 SECONDARY RESEARCH 26
  • 3.3 PRIMARY RESEARCH 27
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 28
  • 3.5 FORECASTING TECHNIQUES 29
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 30
    • 3.6.1 BOTTOM-UP APPROACH 31
    • 3.6.2 TOP-DOWN APPROACH 31
  • 3.7 DATA TRIANGULATION 32
  • 3.8 VALIDATION 32

4 MARKET DYNAMICS

  • 4.1 OVERVIEW 33
  • 4.2 DRIVERS 34
    • 4.2.1 RISING PREVALENCE OF DIABETIC NEUROPATHY 34
    • 4.2.2 INCREASING HEALTHCARE EXPENDITURE 34
    • 4.2.3 GROWING NUMBER OF INCIDENCE OF TRAUMA FROM INJURY AND OTHER CONDITIONS 35
  • 4.3 RESTRAINTS 36
    • 4.3.1 INCREASING COUNTERFEIT DRUGS & SIDE EFFECTS OF THE THERAPEUTIC TREATMENT 36
    • 4.3.2 LACK OF AWARENESS ABOUT THE NEUROLOGICAL CONDITION 37
  • 4.4 OPPORTUNITIES 38
    • 4.4.1 NEW PRODUCT LAUNCH IN DEVELOPING REGIONS 38

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS 39
    • 5.1.1 R&D 40
    • 5.1.2 MANUFACTURING 40
    • 5.1.3 DISTRIBUTION AND SALES 40
    • 5.1.4 POST-SALES MONITORING 40
  • 5.2 PORTER'S FIVE FORCES MODEL 41
    • 5.2.1 BARGAINING POWER OF SUPPLIERS 42
    • 5.2.2 BARGAINING POWER OF BUYERS 42
    • 5.2.3 THREAT OF NEW ENTRANTS 42
    • 5.2.4 THREAT OF SUBSTITUTES 42
    • 5.2.5 INTENSITY OF RIVALRY 42
  • 5.3 IMPACT ANALYSIS OF COVID-19 ON THE GLOBAL NEUROPATHIC PAIN MARKET 43
    • 5.3.1 OVERVIEW 43
    • 5.3.2 IMPACT ON ONGOING TREATMENTS AND DELAYED AVAILABILITY DUE TO DEFERMENT 43
    • 5.3.3 IMPACT ON NUMBER OF PATIENTS 44

6 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE

  • 6.1 OVERVIEW 45
  • 6.2 PERIPHERAL NEUROPATHY 47
  • 6.3 ENTRAPMENT NEUROPATHY 47
  • 6.4 TRIGEMINAL NEURALGIA 48
  • 6.5 PHANTOM LIMB PAIN 48
  • 6.6 POST HERPETIC NEURALGIA (PHN) 49
  • 6.7 POST TRAUMATIC NEUROPATHY 49

7 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION

  • 7.1 OVERVIEW 50
  • 7.2 DIABETIC NEUROPATHY 52
  • 7.3 SPINAL STENOSIS 52
  • 7.4 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY 53
  • 7.5 OTHERS 53

8 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS

  • 8.1 OVERVIEW 54
  • 8.2 IMAGING 55
  • 8.3 BLOOD TESTS 56
  • 8.4 PHYSICAL EXAMINATION 56

9 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT

  • 9.1 OVERVIEW 57
  • 9.2 MEDICATION 58
  • 9.3 MULTIMODAL THERAPY 60

10 GLOBAL NEUROPATHIC PAIN SMARKET, BY DISTRIBUTION CHANNEL

  • 10.1 OVERVIEW 61
  • 10.2 RETAIL PHARMACIES & DRUG STORES 62
  • 10.3 ONLINE PHARMACIES 62

11 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER

  • 11.1 OVERVIEW 63
  • 11.2 HOSPITALS 64
  • 11.3 CLINICS 64
  • 11.4 RESEARCH ORGANIZATIONS 65

12 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION

  • 12.1 OVERVIEW 66
  • 12.2 AMERICAS 67
    • 12.2.1 NORTH AMERICA 72
      • 12.2.1.1 US 77
      • 12.2.1.2 CANADA 81
    • 12.2.2 LATIN AMERICA 85
  • 12.3 EUROPE 90
    • 12.3.1 WESTERN EUROPE 95
      • 12.3.1.1 GERMANY 100
      • 12.3.1.2 UK 104
      • 12.3.1.3 FRANCE 108
      • 12.3.1.4 ITALY 112
      • 12.3.1.5 SPAIN 116
      • 12.3.1.6 REST OF WESTERN EUROPE 120
    • 12.3.2 EASTERN EUROPE 124
  • 12.4 ASIA-PACIFIC 129
    • 12.4.1 CHINA 134
    • 12.4.2 INDIA 138
    • 12.4.3 JAPAN 142
    • 12.4.4 SOUTH KOREA 146
    • 12.4.5 AUSTRALIA 150
    • 12.4.6 REST OF ASIA-PACIFIC 154
  • 12.5 MIDDLE EAST & AFRICA 159
    • 12.5.1 MIDDLE EAST 164
    • 12.5.2 AFRICA 168

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW 173
  • 13.2 COMPETITIVE BENCHMARKING 174
  • 13.3 GLOBAL NEUROPATHIC PAIN MARKET: COMPANY RANKING, 2020 175
  • 13.4 MAJOR GROWTH STRATEGY IN THE GLOBAL NEUROPATHIC PAIN MARKET 175
  • 13.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 176
  • 13.6 COMPETITIVE BENCHMARKING: GLOBAL NEUROPATHIC PAIN MARKET 176
  • 13.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 177
    • 13.7.1 PRODUCT APPROVALS AND LAUNCHES 177
    • 13.7.2 ACQUISITIONS 177
  • 13.8 FINANCIAL MATRIX 178

14 COMPANY PROFILES

  • 14.1 ABBOTT 179
    • 14.1.1 COMPANY OVERVIEW 179
    • 14.1.2 FINANCIAL OVERVIEW 180
    • 14.1.3 PRODUCTS/SERVICES OFFERED 180
    • 14.1.4 KEY DEVELOPMENTS 181
    • 14.1.5 SWOT ANALYSIS 182
    • 14.1.6 KEY STRATEGIES 182
  • 14.2 PFIZER 183
    • 14.2.1 COMPANY OVERVIEW 183
    • 14.2.2 FINANCIAL OVERVIEW 183
    • 14.2.3 PRODUCTS/SERVICES OFFERED 184
    • 14.2.4 KEY DEVELOPMENTS 184
    • 14.2.5 SWOT ANALYSIS 184
    • 14.2.6 KEY STRATEGIES 184
  • 14.3 JOHNSON & JOHNSON SERVICES, INC. 185
    • 14.3.1 COMPANY OVERVIEW 185
    • 14.3.2 FINANCIAL OVERVIEW 186
    • 14.3.3 PRODUCTS/SERVICES OFFERED 186
    • 14.3.4 KEY DEVELOPMENTS 186
    • 14.3.5 SWOT ANALYSIS 187
    • 14.3.6 KEY STRATEGIES 187
  • 14.4 BAXTER INTERNATIONAL 188
    • 14.4.1 COMPANY OVERVIEW 188
    • 14.4.2 FINANCIAL OVERVIEW 188
    • 14.4.3 PRODUCTS/SERVICES OFFERED 189
    • 14.4.4 KEY DEVELOPMENTS 189
    • 14.4.5 SWOT ANALYSIS 189
    • 14.4.6 KEY STRATEGIES 190
  • 14.5 ELI LILY AND COMPANY 190
    • 14.5.1 COMPANY OVERVIEW 190
    • 14.5.2 FINANCIAL OVERVIEW 191
    • 14.5.3 PRODUCTS/SERVICES OFFERED 191
    • 14.5.4 KEY DEVELOPMENTS 191
    • 14.5.5 SWOT ANALYSIS 192
    • 14.5.6 KEY STRATEGIES 192
  • 14.6 GLAXOSMITHKLINE PLC 193
    • 14.6.1 COMPANY OVERVIEW 193
    • 14.6.2 FINANCIAL OVERVIEW 193
    • 14.6.3 PRODUCTS/SERVICES OFFERED 194
    • 14.6.4 KEY DEVELOPMENTS 194
    • 14.6.5 SWOT ANALYSIS 194
    • 14.6.6 KEY STRATEGIES 195
  • 14.7 SANOFI 195
    • 14.7.1 COMPANY OVERVIEW 195
    • 14.7.2 FINANCIAL OVERVIEW 196
    • 14.7.3 PRODUCTS/SERVICES OFFERED 196
    • 14.7.4 KEY DEVELOPMENTS 197
    • 14.7.5 SWOT ANALYSIS 197
    • 14.7.6 KEY STRATEGIES 197
  • 14.8 ASTRAZENECA 198
    • 14.8.1 COMPANY OVERVIEW 198
    • 14.8.2 FINANCIAL OVERVIEW 198
    • 14.8.3 PRODUCTS/SERVICES OFFERED 199
    • 14.8.4 KEY DEVELOPMENTS 199
    • 14.8.5 SWOT ANALYSIS 199
    • 14.8.6 KEY STRATEGIES 199
  • 14.9 DEPOMED INC. (ASSERTIO THERAPEUTICS, INC) 200
    • 14.9.1 COMPANY OVERVIEW 200
    • 14.9.2 FINANCIAL OVERVIEW 200
    • 14.9.3 PRODUCTS/SERVICES OFFERED 200
    • 14.9.4 KEY DEVELOPMENTS 201
    • 14.9.5 SWOT ANALYSIS 201
    • 14.9.6 KEY STRATEGIES 202
  • 14.10 BIOGEN, INC. 202
    • 14.10.1 COMPANY OVERVIEW 202
    • 14.10.2 FINANCIAL OVERVIEW 202
    • 14.10.3 PRODUCTS/SERVICES OFFERED 203
    • 14.10.4 KEY DEVELOPMENTS 203
    • 14.10.5 SWOT ANALYSIS 203
    • 14.10.6 KEY STRATEGIES 203
  • 14.11 ASTELLAS PHARMA LTD. 204
    • 14.11.1 COMPANY OVERVIEW 204
    • 14.11.2 FINANCIAL OVERVIEW 204
    • 14.11.3 PRODUCTS/SERVICES OFFERED 205
    • 14.11.4 KEY DEVELOPMENTS 205
    • 14.11.5 SWOT ANALYSIS 205
    • 14.11.6 KEY STRATEGIES 206

15 APPENDIX

  • 15.1 REFERENCES 207
  • 15.2 RELATED REPORTS 207
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제